Literature DB >> 172318

Induction of human endometrial estradiol dehydrogenase by progestins.

L Tseng, E Gurpide.   

Abstract

Estradiol-17beta dehydrogenase activity in proliferative human endometrium (average of 1.5 nmole of estrone formed from estradiol/mg protein/h) was stimulated as much as as 6-fold during incubations of tissue slices in culture medium containing progesterone. Stimulation was already detectable at 7 h and the highest activity values were reached at 48-72 h of incubation in the presence of excess progesterone. Maximal stimulation was achieved with concentrations of the hormone of 0.25 mug/ml or higher. At concentrations approximately equal to midluteal plasma levels (20 ng/ml) more than 50% of the maximal response was observed. Norgestrel (17alpha-ethynyl-18-methyl-19-nortestosterone) was also effective in inducing enzymatic activity. The similarity of the effects obtained with progesterone (a possible substrate for estradiol dehydrogenase) and the synthetic progestin indicates that the stimulation of enzymatic activity was not due to substrate induction. Addition of estradiol to the culture medium had no influence on the activity of the enzyme. The induction of estradiol dehydrogenase by progesterone was inhibited by puromycin or actinomycin D. These observations indicate that progestational agents increase the rate of de novo synthesis of the enzyme. Stimulation of endometrial estradiol dehydrogenase was also observed after 2-3 day oral administration of medroxyprogesterone acetate to women in the follicular phase. In contrast, the enzymatic activity in endometrium obtained from women taking estrogens was found to be as low as in normal proliferative tissue. These in vitro and in vivo results point to progesterone as the agent responsible for the 10-fold increase in endometrial estradiol dehydrogenase activity observed during the luteal phase in menstruating women. Data obtained from superfusion studies of estrogen dynamics in endometrium indicate that changes in enzyme concentrations may play a physiologic role in the regulation of tissue levels of estradiol.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 172318     DOI: 10.1210/endo-97-4-825

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  35 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  Biomarkers of progestin therapy resistance and endometrial hyperplasia progression.

Authors:  Kristen Upson; Kimberly H Allison; Susan D Reed; Carolyn D Jordan; Katherine M Newton; Elizabeth M Swisher; Jennifer A Doherty; Rochelle L Garcia
Journal:  Am J Obstet Gynecol       Date:  2012-05-16       Impact factor: 8.661

3.  Risk of complex and atypical endometrial hyperplasia in relation to anthropometric measures and reproductive history.

Authors:  Meira Epplein; Susan D Reed; Lynda F Voigt; Katherine M Newton; Victoria L Holt; Noel S Weiss
Journal:  Am J Epidemiol       Date:  2008-08-05       Impact factor: 4.897

4.  The histochemistry of isocitric and oestradiol-17 beta dehydrogenases in the endometrium of postmenopausal women treated with oestrogens and progestogens.

Authors:  G Lane
Journal:  Histochem J       Date:  1990-01

5.  Induction of estradiol dehydrogenase activity in human uterine endometrium by synthetic steroids.

Authors:  J Kitawaki; T Yamamoto; H Okada
Journal:  J Endocrinol Invest       Date:  1988-05       Impact factor: 4.256

Review 6.  A risk-benefit appraisal of transdermal estradiol therapy.

Authors:  A Cheang; R Sitruk-Ware; W H Utian
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

Review 7.  Factors influencing estrogen production and metabolism in postmenopausal women with endocrine cancer.

Authors:  V H James; E J Folkerd; R C Bonney; P A Beranek; M J Reed
Journal:  J Endocrinol Invest       Date:  1982 Sep-Oct       Impact factor: 4.256

8.  Characterization of a new human endometrial carcinoma (RL95-2) established in tissue culture.

Authors:  D L Way; D S Grosso; J R Davis; E A Surwit; C D Christian
Journal:  In Vitro       Date:  1983-03

9.  17 beta-Hydroxysteroid dehydrogenase type 2: chromosomal assignment and progestin regulation of gene expression in human endometrium.

Authors:  M L Casey; P C MacDonald; S Andersson
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

10.  Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020).

Authors:  B L Nguyen; G Chetrite; J R Pasqualini
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.